Collegium Pharmaceutical, Inc.
Symbol: COLL
NASDAQ
37.51
USDTrhová cena dnes
25.1608
Pomer P/E
1.5484
Pomer PEG
1.20B
MRK Cap
- 0.00%
Výnos DIV
Collegium Pharmaceutical, Inc. (COLL) Finančné výkazy
Súvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1210.06 | 310.5 | 173.7 | 186.4 | |||||||||||
balance-sheet.row.short-term-investments | 159.35 | 71.6 | 0 | 0 | |||||||||||
balance-sheet.row.net-receivables | 707.98 | 179.5 | 183.1 | 105.8 | |||||||||||
balance-sheet.row.inventory | 125.38 | 32.3 | 46.5 | 17.4 | |||||||||||
balance-sheet.row.other-current-assets | 51.76 | 0.1 | 16.7 | 0 | |||||||||||
balance-sheet.row.total-current-assets | 2110.28 | 537.6 | 420 | 315.5 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 94.93 | 22 | 26.4 | 27.1 | |||||||||||
balance-sheet.row.goodwill | 535.43 | 133.9 | 133.7 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 1900.47 | 421.7 | 567.5 | 268.7 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 2435.9 | 555.6 | 701.2 | 268.7 | |||||||||||
balance-sheet.row.long-term-investments | 3.52 | 1 | 2.5 | 2.5 | |||||||||||
balance-sheet.row.tax-assets | 100.57 | 26.3 | 23.9 | 78 | |||||||||||
balance-sheet.row.other-non-current-assets | 3.89 | 0.8 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.total-non-current-assets | 2638.81 | 605.7 | 754.1 | 376.5 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 4749.1 | 1143.3 | 1174.1 | 692.1 | |||||||||||
balance-sheet.row.account-payables | 17.76 | 8.7 | 39.6 | 33.4 | |||||||||||
balance-sheet.row.short-term-debt | 737.3 | 184.3 | 163.6 | 49.2 | |||||||||||
balance-sheet.row.tax-payables | 21.59 | 7.1 | 4.4 | 3.2 | |||||||||||
balance-sheet.row.long-term-debt-total | 2223.97 | 490 | 709.2 | 258.8 | |||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 1015.23 | 264.9 | 66.9 | 147.8 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 2223.97 | 490 | 709.2 | 258.8 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 29.98 | 7.1 | 8.2 | 8.8 | |||||||||||
balance-sheet.row.total-liab | 3994.26 | 947.9 | 979.3 | 489.1 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0.15 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.retained-earnings | -1082.85 | -233.2 | -281.3 | -256.3 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.08 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 1837.62 | 428.6 | 476.1 | 459.2 | |||||||||||
balance-sheet.row.total-stockholders-equity | 754.84 | 195.4 | 194.8 | 202.9 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 4749.1 | 1143.3 | 1174.1 | 692.1 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 754.84 | 195.4 | 194.8 | 202.9 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 4749.1 | - | - | - | |||||||||||
Total Investments | 161.9 | 71.6 | 2.5 | 2.5 | |||||||||||
balance-sheet.row.total-debt | 2961.26 | 674.3 | 872.8 | 258.8 | |||||||||||
balance-sheet.row.net-debt | 1910.56 | 435.3 | 699.1 | 72.3 |
Výkaz peňažných tokov
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 48.16 | 48.2 | -25 | 71.5 | |||||||||||
cash-flows.row.depreciation-and-amortization | 149.26 | 149.3 | 138.9 | 68.9 | |||||||||||
cash-flows.row.deferred-income-tax | -2.15 | -2.2 | -8.4 | -78 | |||||||||||
cash-flows.row.stock-based-compensation | 27.14 | 27.1 | 22.9 | 24.3 | |||||||||||
cash-flows.row.change-in-working-capital | 21.73 | 21.7 | -12.7 | 13.5 | |||||||||||
cash-flows.row.account-receivables | 3.59 | 3.6 | -21.8 | -22.5 | |||||||||||
cash-flows.row.inventory | 14.17 | 14.2 | 48.3 | -2.3 | |||||||||||
cash-flows.row.account-payables | 5.06 | 5.1 | -0.7 | -5.8 | |||||||||||
cash-flows.row.other-working-capital | 23.77 | -1.1 | -38.5 | 44.1 | |||||||||||
cash-flows.row.other-non-cash-items | 30.62 | 30.6 | 8.5 | 3.4 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 274.75 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.46 | -0.5 | -1.6 | -1.9 | |||||||||||
cash-flows.row.acquisitions-net | -41.66 | 0 | -572.1 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | -92.35 | -92.4 | 0 | 0 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 22 | 22 | 0 | 0 | |||||||||||
cash-flows.row.other-investing-activites | 41.66 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -70.81 | -70.8 | -573.7 | -1.9 | |||||||||||
cash-flows.row.debt-repayment | -301.14 | -301.1 | -75 | -50 | |||||||||||
cash-flows.row.common-stock-issued | 1.84 | 9.1 | 11.8 | 12.7 | |||||||||||
cash-flows.row.common-stock-repurchased | -75.05 | -75 | -14.1 | -47.9 | |||||||||||
cash-flows.row.dividends-paid | -57.53 | -9.1 | 0 | -12.7 | |||||||||||
cash-flows.row.other-financing-activites | 291.69 | 236 | 514 | 8.6 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -140.18 | -140.2 | 436.7 | -89.3 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 63.76 | 63.8 | -12.7 | 12.3 | |||||||||||
cash-flows.row.cash-at-end-of-period | 1056.4 | 240 | 176.2 | 189 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 992.64 | 176.2 | 189 | 176.7 | |||||||||||
cash-flows.row.operating-cash-flow | 274.75 | 274.7 | 124.2 | 103.6 | |||||||||||
cash-flows.row.capital-expenditure | -0.46 | -0.5 | -1.6 | -1.9 | |||||||||||
cash-flows.row.free-cash-flow | 274.29 | 274.3 | 122.6 | 101.6 |
Riadok výkazu ziskov a strát
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 566.77 | 566.8 | 463.9 | 276.9 | |||||||||||
income-statement-row.row.cost-of-revenue | 240.6 | 240.6 | 254.4 | 126.3 | |||||||||||
income-statement-row.row.gross-profit | 326.17 | 326.2 | 209.5 | 150.6 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.operating-expenses | 159.21 | 159.2 | 176.2 | 128.4 | |||||||||||
income-statement-row.row.cost-and-expenses | 399.81 | 399.8 | 430.6 | 254.7 | |||||||||||
income-statement-row.row.interest-income | 15.62 | 15.6 | 1 | 0 | |||||||||||
income-statement-row.row.interest-expense | 83.34 | 83.3 | 63.2 | 21 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -91.23 | -23.5 | 75.7 | 43.3 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.total-operating-expenses | -91.23 | -23.5 | 75.7 | 43.3 | |||||||||||
income-statement-row.row.interest-expense | 83.34 | 83.3 | 63.2 | 21 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 152 | 149.3 | 138.9 | 68.9 | |||||||||||
income-statement-row.row.ebitda-caps | 331.83 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 166.96 | 167 | -104.6 | -46.7 | |||||||||||
income-statement-row.row.income-before-tax | 75.73 | 75.7 | -28.8 | -3.4 | |||||||||||
income-statement-row.row.income-tax-expense | 27.58 | 27.6 | -3.8 | -74.9 | |||||||||||
income-statement-row.row.net-income | 48.16 | 48.2 | -25 | 71.5 |
Často kladené otázky
Čo je Collegium Pharmaceutical, Inc. (COLL) celkové aktíva?
Collegium Pharmaceutical, Inc. (COLL) celkové aktíva sú 1143308000.000.
Aký je ročný obrat podniku?
Ročné príjmy sú 286454000.000.
Aké je ziskové rozpätie podniku?
Zisková marža firmy je 0.575.
Aký je voľný peňažný tok podniku?
Voľný peňažný tok je 8.492.
Aká je čistá zisková marža podniku?
Čistá zisková marža je 0.085.
Aké sú celkové výnosy podniku?
Celkové príjmy sú 0.295.
Aká je Collegium Pharmaceutical, Inc. (COLL) čistý zisk (čistý príjem)?
Čistý zisk (čistý príjem) je 48155000.000.
Aký je celkový dlh firmy?
Celkový dlh je 674283000.000.
Aké je číslo prevádzkových nákladov?
Prevádzkové výdavky sú 159208000.000.
Aký je údaj o hotovosti spoločnosti?
Peňažné prostriedky podniku sú 238947000.000.